Oramed's insulin capsule is designed for the early stage of type 2 diabetes treatment.
Castro is disappointed with Carolina Lemke's results in the US, and is terminating its agreement with Kardashian.
The company says that the agreement with Alvotech will generate $20-30 million peak annual revenue.
Rosenblum is offering NIS 4 million for the stock exchange shell.
The Be chain, acquired two years ago from Hamashbir Lazarchan as New Pharm, will close 6% of its branches in 2020.
Ari Bronshtein is the latest in a series of IDB Development-Discount Investment group executives who have decided to leave.
The new method is designed to provide more powerful and focused treatment.
The company has developed a way of precisely adapting antibiotics to infections.
XACT Robotics has developed a device, with FDA approval and CE Mark, for guiding instruments to precise locations in the body.
Overall, group revenue and margins rose in the third quarter, but high finance expenses cut profit
The Wall Street Journal reports that Teva and other companies are being investigated on the basis of laws against drug dealers.
Teva aims to strengthen its ties with institutions of higher education in Israel and bring brains back to Israel.
According to Bloomberg, in talks with the US Justice Department, Teva and other companies will admit some of the allegations and pay fines.
Cannbit will pay $23 million immediately plus 4.99% of its shares for Tikun Olam's Israel activity, plus $18 million conditional on revenue.
The ARC center fosters local and international collaboration for digital healthcare projects, with on the spot input from doctors and nurses.
Former Teva CEO Jeremy Levin talks to "Globes" about Israel's biotech potential, the opioid disaster and why he shuns investing in medical cannabis.